Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Eur Urol Oncol. 2019 Apr 5;2(6):643–648. doi: 10.1016/j.euo.2019.03.007

Table 2 –

Baseline treatment characteristics for the CN and no-CN groups.

No CN (N = 109) CN (N = 244) p value
First-line therapy, n/N (%)
 Sunitinib 59/109 (54) 134/244 (55)
 Sorafenib 3/109 (2.8) 31/244 (13)
 Temsirolimus 25/109 (23) 31/244 (13)
 Pazopanib 12/109 (11) 19/244 (7.8)
 Other 10/109 (9.1) 29/244 (12)
Second-line therapy, n/N (%) 43/109 (39) 137/244 (56) 0.0037
Third-line therapy, n/N (%) 17/109 (16) 58/244 (24) 0.0828
Fourth-line therapy, n/N (%) 4/109 (3.7) 16/244 (6.6) 0.2783

CN = cytoreductive nephrectomy.